# Thierry Facon

Source: https://onco.cc/people/thierry-facon/  
OnCo record `thierry-facon` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led MAIA, which made daratumumab-lenalidomide-dexamethasone the standard for older patients with myeloma.

## Summary

Thierry Facon (Lille) was principal investigator of MAIA, the trial showing daratumumab plus lenalidomide-dexamethasone dramatically improves progression-free and overall survival in transplant-ineligible newly diagnosed myeloma, with median survival now beyond seven years, and of FIRST, which established continuous lenalidomide-dexamethasone in this population. He led the IFM frailty score work and co-leads the IMROZ isatuximab trial.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: myeloma; older-patients; trialist
- Role: Professor of Hematology, Lille University Hospital (CHU Lille)
- Specialisms: Multiple myeloma; Older and transplant-ineligible patients; Daratumumab; Frailty

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Facon%20T%5BAuthor%5D%20myeloma%20daratumumab%20MAIA

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- technologies: [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- targets: [CD38](https://onco.cc/targets/cd38/)
- institutions: [Lille University Hospital (CHU de Lille)](https://onco.cc/institutions/chu-lille/)
- trials: [IMROZ](https://onco.cc/trials/imroz/), [MAIA](https://onco.cc/trials/maia/)
- key papers: [MAIA: adding daratumumab to lenalidomide-dexamethasone for older patients with newly diagnosed myeloma who cannot have a transplant](https://onco.cc/key-papers/paper-maia-daratumumab-rd-nejm-2019/)

---
JSON: https://onco.cc/api/v1/entities/thierry-facon.json